Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

HRES 685 is a non-binding resolution expressing support for adding antiphospholipid syndrome (APS) testing to standard prenatal screening. APS is an immune condition causing blood clots that can lead to miscarriages and stillbirths, currently not tested for routinely despite causing about 15% of recurrent pregnancy losses. The resolution urges medical associations to update guidelines to recommend APS testing as standard during prenatal care, rather than only for women with specific histories of pregnancy loss. It does not change current medical practice but advocates for updated recommendations to potentially prevent pregnancy complications.